Obermatt
See Similar Stocks →

KYORIN Holdings

TYO:4569 · JP3247090008
PharmaceuticalsMedium

360

57
EV / EBIT13
Price / Owner Earnings13
Owner Earnings Yield69
Dividend Yield81
Price/Sales96
EV / Gross Profit91
Price/Book100
Return on Capital57
Cash Return on Capital58
Return on Equity59
EBIT Margin43
Gross Profitability56
Cash Conversion81
Accruals59
Owner Earnings Margin56
Sales growth1
Profit Growth8
Long-Term EPS Growth16
Reinvestment59
Price momentum30
Debt load64
Refinancing96
Debt Payback12
Liquidity70
Analyst ratings1
Opinion Changes50
Price Target Upside4
Market mood49
Value Creation3/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

KYORIN Holdings doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryJapan
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeTSE
Founded1958
Websitekyorin-pharm.co.jp
ISINJP3247090008
Last UpdateApr 2, 2026
Index & Theme
Chronic DiseasesAllergyUrologyPulmonologyRespiratoryGastroenterologyEar Nose & Throat (ENT)BiotechnologyInformation TechnologyMedicalPharmaceutical

Description

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells ethical and generic drugs. Business Segments The company operates through several segments, each of which plays a distinct role in its overa…

Analysis

Middle-of-the-road

KYORIN Pharmaceutical Co., Ltd. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

On valuation, the picture is attractive. The owner-earnings multiple stands at 14.5×; owner earnings: the cash an owner could take out each year.

Growth is tepid; the safety picture is adequate. The company scores 3/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
53
2023202420252026

All-time high

64

Mar 2026

All-time low

41

Jan 2025

Average rank

52

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
96
93
89
91
Price/Earnings
54
79
42
38
Price/Book
100
97
91
91
Dividend Yield
81
89
87
85
Value (overall)
100
100
90
83

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare KYORIN Holdings with its peers
Neuren Pharmaceuticals
ASX:NEU
29
CountryAustralia
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Jyong Biotech
NMQ:MENS
—
CountryTaiwan
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Clarity Pharmaceuticals
ASX:CU6
8
CountryAustralia
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kyowa Hakko Kirin
TYO:4151
50
CountryJapan
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Eisai
TYO:4523
70
CountryJapan
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Takaras
TYO:2531
28
CountryJapan
IndustryBeverages
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →